



## **Aoxin Q & M Dental Group Limited**

### Condensed Interim Financial Statements For the Six Months and Full Year Ended 31 December 2025

---

This announcement has been reviewed by the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).

<b>Content</b>	<b>Page</b>
<b>Condensed interim consolidated statements of profit or loss and other comprehensive income</b>	<b>1</b>
<b>Condensed interim statements of financial position</b>	<b>3</b>
<b>Condensed interim statements of changes in equity</b>	<b>4</b>
<b>Condensed interim consolidated statements of cash flows</b>	<b>6</b>
<b>Notes to the condensed interim consolidated financial statements</b>	<b>7</b>
<b>Other information required by Catalist Rule Appendix 7C</b>	<b>19</b>

## Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income

	Notes	Group			Group		
		Unaudited	Unaudited	Change	Unaudited	Unaudited	Change
		2H2025	2H2024		FY2025	FY2024	
RMB'000	RMB'000	%	RMB'000	RMB'000	%		
			<i>Restated<sup>a</sup></i>		<i>Restated<sup>a</sup></i>		
<b>Revenue</b>							
Primary healthcare		48,118	58,461	(17.7)	103,018	113,017	(8.8)
Distribution of dental equipment and supplies		24,241	23,971	1.1	44,140	41,639	6.0
Laboratory services		11,870	12,034	(1.4)	23,890	22,829	4.6
Total revenue	4	84,229	94,466	(10.8)	171,048	177,485	(3.6)
Interest income		124	65	90.8	249	116	NM
Other income and gains	5	5,396	2,280	NM	5,857	3,525	66.2
<b>Expenses</b>							
Consumables and dental supplies		(7,099)	(8,938)	(20.6)	(14,992)	(17,318)	(13.4)
Cost of sales in dental equipment and supplies		(20,856)	(20,908)	(0.2)	(38,262)	(35,675)	7.3
Cost of laboratory services		(2,301)	(2,573)	(10.6)	(4,636)	(5,217)	(11.1)
Employee benefits expenses		(36,615)	(40,049)	(8.6)	(74,723)	(79,398)	(5.9)
Depreciation and amortisation expenses		(4,347)	(3,964)	9.7	(8,513)	(8,361)	1.8
Depreciation of right-of-use assets		(3,052)	(3,344)	(8.7)	(6,255)	(6,604)	(5.3)
Finance costs	6	(454)	(727)	(37.6)	(967)	(1,489)	(35.1)
Other expenses		(8,329)	(10,147)	(17.9)	(17,671)	(18,586)	(4.9)
Other losses	5	(1,080)	(785)	37.6	(2,710)	(812)	NM
<b>Profit before tax, excluding share of results of associate</b>		5,616	5,376	4.5	8,425	7,666	9.9
Share of results of associate		(257)	(16,914)	(98.5)	(29)	(14,237)	(99.8)
<b>Profit / (loss) before tax</b>		5,359	(11,538)	NM	8,396	(6,571)	NM
Income tax expense	7	(1,161)	(1,368)	(15.1)	(1,462)	(1,426)	2.5
<b>Profit / (loss), net of tax</b>		4,198	(12,906)	NM	6,934	(7,997)	NM
<b>Other comprehensive income / (loss)</b>							
<i>Item that may be reclassified subsequently to profit or loss</i>							
Exchange differences on translation to presentation currency		(2,042)	15	NM	324	49	NM
<b>Total comprehensive income / (loss)</b>		2,156	(12,891)	NM	7,258	(7,948)	NM
<b>Profit/(loss), net of tax attributable to:</b>							
Owners of the Company		4,237	(12,907)	NM	6,973	(7,998)	NM
Non-controlling interests		(39)	1	NM	(39)	1	NM
		4,198	(12,906)	NM	6,934	(7,997)	NM
<b>Total comprehensive income / (loss) attributable to:</b>							
Owners of the Company		2,195	(12,892)	NM	7,297	(7,949)	NM
Non-controlling interests		(39)	1	NM	(39)	1	NM
		2,156	(12,891)	NM	7,258	(7,948)	NM

<sup>a</sup> Refer to Note 20 for further information.

Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income  
(cont'd)

	<u>Unaudited</u> <u>2H2025</u> RMB'000	<u>Unaudited</u> <u>2H2024</u> RMB'000 <i>Restated<sup>a</sup></i>	<u>Change</u> %	<u>Unaudited</u> <u>FY2025</u> RMB'000	<u>Unaudited</u> <u>FY2024</u> RMB'000 <i>Restated<sup>a</sup></i>	<u>Change</u> %
<b>Profit/(loss), net of tax excluding share of results of associate</b>						
Owners of the Company	4,494	4,007	12.2	7,002	6,239	12.2
Non-controlling interests	(39)	1	NM	(39)	1	NM
	<u>4,455</u>	<u>4,008</u>	<u>11.2</u>	<u>6,963</u>	<u>6,240</u>	<u>11.6</u>

	RMB Cents	RMB Cents <i>Restated<sup>a</sup></i>	%	RMB Cents	RMB Cents <i>Restated<sup>a</sup></i>	%	
<b>Earnings per share (loss)</b>							
– Basic	8	0.79	(2.52)	NM	1.30	(1.56)	NM
– Diluted	8	0.79	(2.52)	NM	1.30	(1.56)	NM

NM: Not meaningful.

<sup>a</sup> Refer to Note 20 for further information.

## Condensed Interim Statements of Financial Position

	Notes	Group		Company	
		Unaudited FY2025 RMB'000	Unaudited FY2024 RMB'000 <i>Restated<sup>a</sup></i>	Unaudited FY2025 RMB'000	Audited FY2024 RMB'000
<b>ASSETS</b>					
<b>Non-current assets</b>					
Property, plant and equipment	9	22,236	28,427	5	12
Right-of-use assets		17,524	23,446	246	489
Goodwill	10	125,219	125,219	–	–
Intangible assets		1,324	2,090	47	93
Investments in subsidiaries		–	–	315,933	310,958
Investment in an associate	11	6,794	6,716	6,794	6,716
Deferred tax assets		978	978	–	–
Other receivables		–	–	6,529	6,426
Other non-financial assets		12	49	–	15
<b>Total non-current assets</b>		<b>174,087</b>	<b>186,925</b>	<b>329,554</b>	<b>324,709</b>
<b>Current assets</b>					
Inventories		9,638	10,320	–	–
Trade and other receivables		48,667	39,908	21,129	18,604
Other non-financial assets		2,386	1,767	107	154
Cash and cash equivalents		148,708	69,937	100,401	21,965
<b>Total current assets</b>		<b>209,399</b>	<b>121,932</b>	<b>121,637</b>	<b>40,723</b>
<b>Total assets</b>		<b>383,486</b>	<b>308,857</b>	<b>451,191</b>	<b>365,432</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Equity</b>					
Share capital	12	528,524	445,723	528,524	445,723
Accumulated losses		(142,589)	(149,320)	(137,695)	(136,899)
(Adverse balance) / other reserves		(37,178)	(37,744)	58,040	52,612
<b>Equity attributable to owners of the Company</b>		<b>348,757</b>	<b>258,659</b>	<b>448,869</b>	<b>361,436</b>
Non-controlling interests		517	1	–	–
<b>Total equity</b>		<b>349,274</b>	<b>258,660</b>	<b>448,869</b>	<b>361,436</b>
<b>Non-current liabilities</b>					
Deferred tax liabilities		204	346	–	–
Lease liabilities		7,246	10,945	–	246
<b>Total non-current liabilities</b>		<b>7,450</b>	<b>11,291</b>	<b>–</b>	<b>246</b>
<b>Current liabilities</b>					
Income tax payable		312	425	35	–
Trade and other payables		21,235	31,451	2,056	3,173
Lease liabilities		5,215	6,691	231	238
Other financial liabilities	14	–	339	–	339
<b>Total current liabilities</b>		<b>26,762</b>	<b>38,906</b>	<b>2,322</b>	<b>3,750</b>
<b>Total liabilities</b>		<b>34,212</b>	<b>50,197</b>	<b>2,322</b>	<b>3,996</b>
<b>Total equity and liabilities</b>		<b>383,486</b>	<b>308,857</b>	<b>451,191</b>	<b>365,432</b>

<sup>a</sup> Refer to Note 20 for further information.

## Aoxin Q & M Dental Group Limited

### Condensed Interim Statements of Changes in Equity

<b>Group</b>	<b>Total equity</b> RMB'000	<b>Attributable to owners of the Company</b> RMB'000	<b>Share capital</b> RMB'000	<b>Accumulated losses</b> RMB'000	<b>Other reserve</b> RMB'000	<b>Statutory reserve</b> RMB'000	<b>Share-based payment reserve</b> RMB'000	<b>Foreign currency translation reserve</b> RMB'000	<b>Non-controlling interest</b> RMB'000
<b>Current year</b>									
Opening balance at 1 January 2025 (Restated) <sup>a</sup>	258,660	258,659	445,723	(149,320)	(71,920)	10,123	6,736	17,317	1
Total comprehensive income/ (loss) for the year	7,258	7,297	–	6,973	–	–	–	324	(39)
Transfer to statutory reserve	–	–	–	(242)	–	242	–	–	–
Issuance of new shares (Note 12)	82,801	82,801	82,801	–	–	–	–	–	–
Capital contribution by non-controlling interests	555	–	–	–	–	–	–	–	555
Closing balance at 31 December 2025	<u>349,274</u>	<u>348,757</u>	<u>528,524</u>	<u>(142,589)</u>	<u>(71,920)</u>	<u>10,365</u>	<u>6,736</u>	<u>17,641</u>	<u>517</u>
<b>Previous year</b>									
Opening balance at 1 January 2024	267,025	267,025	445,473	(140,268)	(71,920)	9,069	7,403	17,268	–*
Total comprehensive income/ (loss) for the year (Previously reported)	(1,711)	(1,712)	–	(1,761)	–	–	–	49	1
Restatement <sup>a</sup> (Note 20)	(6,237)	(6,237)	–	(6,237)	–	–	–	–	–
Total comprehensive income/ (loss) for the year (Restated) <sup>a</sup>	(7,948)	(7,949)	–	(7,998)	–	–	–	49	1
Transfer to statutory reserve	–	–	–	(1,054)	–	1,054	–	–	–
Share-based payments <sup>b</sup>	(667)	(667)	–	–	–	–	(667)	–	–
Issuance of new shares (Note 12)	250	250	250	–	–	–	–	–	–
Closing balance at 31 December 2024 (Restated) <sup>a</sup>	<u>258,660</u>	<u>258,659</u>	<u>445,723</u>	<u>(149,320)</u>	<u>(71,920)</u>	<u>10,123</u>	<u>6,736</u>	<u>17,317</u>	<u>1</u>

\* Representing amount less than RMB1,000.

**Condensed Interim Statements of Changes in Equity (cont'd)**

<b>Company</b>	Total equity RMB'000	Share capital RMB'000	Accumulated losses RMB'000	Share-based payment reserve RMB'000	Foreign currency translation reserve RMB'000
<b>Current year</b>					
Opening balance at 1 January 2025	361,436	445,723	(136,899)	6,736	45,876
Total comprehensive income/ (loss) for the year	4,632	–	(796)	–	5,428
Issuance of new shares (Note 12)	82,801	82,801	–	–	–
Closing balance at 31 December 2025	<u>448,869</u>	<u>528,524</u>	<u>(137,695)</u>	<u>6,736</u>	<u>51,304</u>
<b>Previous year</b>					
Opening balance at 1 January 2024	374,929	445,473	(123,801)	7,403	45,854
Total comprehensive income/ (loss) for the year	(13,076)	–	(13,098)	–	22
Share-based payments <sup>b</sup>	(667)	–	–	(667)	–
Issuance of new shares (Note 12)	250	250	–	–	–
Closing balance at 31 December 2024	<u>361,436</u>	<u>445,723</u>	<u>(136,899)</u>	<u>6,736</u>	<u>45,876</u>

**Note:**

<sup>a</sup> Refer to Note 20 for further information.

<sup>b</sup> Unvested shares awarded had lapsed as the clinic where the employee was employed has ceased operation at end of October 2024 and the employee has left the Group.

## Condensed Interim Consolidated Statements of Cash Flows

	<b>Group</b>			
	<b>Unaudited</b> <b>2H2025</b> <b>RMB'000</b>	<b>Unaudited</b> <b>2H2024</b> <b>RMB'000</b> <i>Restated<sup>a</sup></i>	<b>Unaudited</b> <b>FY2025</b> <b>RMB'000</b>	<b>Unaudited</b> <b>FY2024</b> <b>RMB'000</b> <i>Restated<sup>a</sup></i>
<b><u>Cash flows from operating activities</u></b>				
Profit /(loss) before tax	5,359	(11,538)	8,396	(6,571)
Depreciation of plant and equipment	3,953	3,587	7,745	7,485
Amortisation of intangible assets	394	377	768	876
Depreciation of right-of-use assets	3,052	3,344	6,255	6,604
Plant and equipment written-off	204	575	278	576
Intangible assets written-off	20	–	20	–
Gain on remeasurement/derecognised of right-of-use assets and lease liabilities	(403)	(347)	(226)	(465)
Net (reversal)/ allowance for impairment on trade receivables	(42)	(39)	8	(13)
Impairment allowance on non-trade receivables	–	–	500	–
Bad debts (reversal)/written-off	(264)	56	522	56
Unrealised foreign exchange losses/(gains)	3,148	(10)	402	(2)
Interest expense	454	727	967	1,489
Share-based payments	–	(417)	–	(417)
Loss on disposal of plant and equipment	98	–	96	–
Inventories (written back)/written-down	(80)	69	(107)	70
Share of results of associate	257	16,914	29	14,237
Operating cash flows before changes in working capital	16,150	13,298	25,653	23,925
Inventories	2,387	1,836	789	685
Trade and other receivables	(6,290)	(5,525)	(9,789)	(2,417)
Other non-financial assets	(1,130)	(106)	(582)	53
Trade and other payables	(5,578)	10,046	(10,216)	8,304
Net cash flows from operations	5,539	19,549	5,855	30,550
Income taxes paid	(1,271)	(170)	(1,717)	(360)
Net cash flows from operating activities	4,268	19,379	4,138	30,190
<b><u>Cash flows used in from investing activities</u></b>				
Acquisition of plant and equipment	(1,054)	(1,414)	(2,206)	(2,093)
Acquisition of intangible assets - software	–	–	–	(60)
Proceed from disposal of plant and equipment	254	–	257	–
Net cash flows used in investing activities	(800)	(1,414)	(1,949)	(2,153)
<b><u>Cash flows generated from /(used in) financing activities</u></b>				
Repayments of bank loans and bill payable	–	(345)	(347)	(684)
Interest expense paid	–	(6)	(2)	(16)
Payment of principal portion of lease liabilities	(3,147)	(4,720)	(5,274)	(7,109)
Payment of interest portion of lease liabilities	(454)	(721)	(965)	(1,473)
Proceeds from issuance of new shares	82,801	–	82,801	–
Net cash flows generated from /(used in) financing activities	79,200	(5,792)	76,213	(9,282)
<b>Net increase in cash and cash equivalents</b>	<b>82,668</b>	<b>12,173</b>	<b>78,402</b>	<b>18,755</b>
Cash and cash equivalents, beginning balance	66,840	57,775	69,937	51,184
Effect of foreign exchange rate changes on cash and cash equivalents	(800)	(11)	369	(2)
<b>Cash and cash equivalents, ending balance</b>	<b>148,708</b>	<b>69,937</b>	<b>148,708</b>	<b>69,937</b>

<sup>a</sup> Refer to Note 20 for further information.

# Aoxin Q & M Dental Group Limited

## Notes to the Condensed Interim Consolidated Financial Statements For The Financial Year Ended 31 December 2025

### 1. General

Aoxin Q & M Dental Group Limited (the “**Company**”) is incorporated in Singapore with limited liability. It is listed on the Catalist Board of Singapore Exchange Securities Trading Limited.

The financial statements are presented in Chinese Renminbi (“**RMB**”) and they cover the Company and its subsidiaries (collectively, the “**Group**”). All information in these financial statements are rounded to the nearest thousand (“**RMB’000**”), except when otherwise indicated.

The board of directors approved and authorised these condensed interim financial statements for issue on the date of this announcement. The directors have the power to amend and reissue the financial statements.

The principal activity of the Company is investment holding. The principal activities of the subsidiaries are disclosed in Note 3 on Financial information by operating segments.

The latest audited annual financial statements for the reporting year ended 31 December 2024 were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

#### Basis of preparation

These condensed interim consolidated financial statements have been prepared in accordance with the Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 Interim Financial Reporting issued by the Accounting Standards Committee under Accounting and Corporate Regulatory Authority (“**ASC**”). They are also in compliance with the International Financial Reporting Standards issued by the International Accounting Standards Board.

The accounting policies and methods of computation applied in these condensed interim financial statements are consistent with those of the latest audited annual financial statements for the reporting year ended 31 December 2024. The Group has adopted all the new and revised SFRS (I) that are relevant to its operations and effective for the current reporting year. The adoption of these new/revised SFRS(I)s did not result in material changes to the Group’s accounting policies and has no material effect on the financial results or position of the Group and of the Company. The typical notes and information included in the latest audited annual financial statements are not included in these interim financial statements except for the selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the performance and financial position the Group since the latest audited annual financial statements. Accordingly, these financial statements are to be read in conjunction with the Group’s annual financial statements for the reporting year ended 31 December 2024. The Company’s separate financial statements have been prepared on the same basis.

## 1. General (cont'd)

### Critical judgements, assumptions and estimation uncertainties

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the latest audited annual financial statements for the reporting year ended 31 December 2024.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are as follows:

- Assessment of impairment of goodwill
- Assessment of carrying values of property, plant and equipment, other intangible assets and right-of-use assets
- Estimation of useful lives of property, plant and equipment
- Assessment of impairment loss on subsidiaries
- Assessment of impairment loss on associate
- Assessment of loss allowance on inventories
- Assessment of expected credit loss allowance on trade receivables
- Estimation of income tax amounts

## 2. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the reporting period.

## 3. Financial information by operating segments

### 3A. Information about reportable segment profit or loss, assets and liabilities

The segments and the types of products and services are as follows:

- (i) Primary healthcare comprising dentistry services;
- (ii) Distribution of dental equipment and supplies, which includes, amongst others, the distribution of equipment and supplies used in the provision of dental services; and
- (iii) Laboratory services comprising the manufacturing of porcelain crown, bridges and dentures.

## Aoxin Q & M Dental Group Limited

### 3B. Profit or loss for the year and reconciliations

	<u>Primary healthcare</u>		<u>Distribution of dental equipment and supplies</u>		<u>Laboratory services</u>		<u>Consolidated</u>	
	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000 <i>Restated<sup>a</sup></i>	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000 <i>Restated<sup>a</sup></i>
<b>Revenue</b>								
Revenue from external customers (Note 4)	103,018	113,017	44,140	41,639	23,890	22,829	171,048	177,485
Inter-segment revenue	14,004	34,925	9,627	10,711	9,222	12,804	32,853	58,440
Total revenue	<u>117,022</u>	<u>147,942</u>	<u>53,767</u>	<u>52,350</u>	<u>33,112</u>	<u>35,633</u>	<u>203,901</u>	<u>235,925</u>
Segment results excludes								
unallocated corporate expenses	29,411	42,457	672	474	1,954	(12,533)	32,037	30,398
Unallocated corporate expenses							(7,906)	(20,515)
Finance costs							(967)	(1,489)
Depreciation of plant and equipment							(7,745)	(7,485)
Depreciation of right-of-use assets							(6,255)	(6,604)
Amortisation of intangible assets							(768)	(876)
Profit/(loss) before income tax							8,396	(6,571)
Income tax expense							(1,462)	(1,426)
<b>Profit/(loss), net of tax</b>							<u>6,934</u>	<u>(7,997)</u>
<b>Additions to non-current assets</b>								
Property, plant and equipment	<u>1,383</u>	<u>1,441</u>	<u>19</u>	<u>17</u>	<u>804</u>	<u>635</u>	<u>2,206</u>	<u>2,093</u>
<b>Other material non-cash items</b>								
Depreciation of plant and equipment	6,839	6,618	19	18	887	849	7,745	7,485
Depreciation of right-of-use assets	5,837	6,235	83	115	335	254	6,255	6,604
Amortisation of intangible assets	296	403	42	42	430	431	768	876
Plant and equipment written-off	278	576	–	–	–	–	278	576
Impairment on trade receivables								
- (reversal)/allowance	–	(28)	(60)	(40)	68	55	8	(13)
Impairment allowance on non-trade receivables	500	–	–	–	–	–	500	–
Bad debts written-off	522	56	–	–	–	–	522	56
Share-based payment								
- (reversal)/expense	–	(417)	–	–	–	–	–	(417)
<b>Segment assets</b>	<u>320,848</u>	<u>256,024</u>	<u>21,763</u>	<u>19,345</u>	<u>40,875</u>	<u>33,488</u>	<u>383,486</u>	<u>308,857</u>
<b>Segment liabilities</b>	<u>23,522</u>	<u>41,200</u>	<u>2,906</u>	<u>3,784</u>	<u>7,784</u>	<u>5,213</u>	<u>34,212</u>	<u>50,197</u>

<sup>a</sup> Refer to Note 20 for further information.

## Aoxin Q & M Dental Group Limited

### 3B. Profit or loss for the second half year and reconciliations

	<u>Primary healthcare</u>		<u>Distribution of dental equipment and supplies</u>		<u>Laboratory services</u>		<u>Consolidated</u>	
	<u>2H2025</u> RMB'000	<u>2H2024</u> RMB'000 <i>Restated<sup>a</sup></i>	<u>2H2025</u> RMB'000	<u>2H2024</u> RMB'000	<u>2H2025</u> RMB'000	<u>2H2024</u> RMB'000	<u>2H2025</u> RMB'000	<u>2H2024</u> RMB'000 <i>Restated<sup>a</sup></i>
<b>Revenue</b>								
Revenue from external customers (Note 4)	48,118	58,461	24,241	23,971	11,870	12,034	84,229	94,466
Inter-segment revenue	(1,503)	18,119	4,468	5,537	3,878	5,863	6,843	29,519
Total revenue	<u>46,615</u>	<u>76,580</u>	<u>28,709</u>	<u>29,508</u>	<u>15,748</u>	<u>17,897</u>	<u>91,072</u>	<u>123,985</u>
Segment results excludes								
unallocated corporate expense	15,001	29,643	986	364	(66)	(16,164)	15,921	13,843
Unallocated corporate expense							(2,709)	(17,346)
Finance costs							(454)	(727)
Depreciation of plant and equipment							(3,953)	(3,587)
Depreciation of right-of-use assets							(3,052)	(3,344)
Amortisation of intangible assets							(394)	(377)
Profit/(loss) before income tax							5,359	(11,538)
Income tax expense							(1,161)	(1,368)
<b>Profit/(loss), net of tax</b>							<u>4,198</u>	<u>(12,906)</u>
<b>Additions to non-current assets</b>								
Property, plant and equipment	<u>576</u>	<u>879</u>	<u>17</u>	<u>17</u>	<u>461</u>	<u>518</u>	<u>1,054</u>	<u>1,414</u>
<b>Other material non-cash items</b>								
Depreciation of plant and equipment	3,502	3,215	10	(45)	441	417	3,953	3,587
Depreciation of right-of-use assets	2,822	3,146	41	56	189	142	3,052	3,344
Amortisation of intangible assets	158	140	21	22	215	215	394	377
Plant and equipment written-off	204	575	–	–	–	–	204	575
Impairment on trade receivables								
- allowance/(reversal)	(12)	–	(60)	(77)	30	38	(42)	(39)
Bad debts (reversal)/written-off	(264)	56	–	–	–	–	(264)	56
Share-based payment								
- (reversal)/expense	–	(417)	–	–	–	–	–	(417)
<b>Segment assets</b>	<u>320,848</u>	<u>256,024</u>	<u>21,763</u>	<u>19,345</u>	<u>40,875</u>	<u>33,488</u>	<u>383,486</u>	<u>308,857</u>
<b>Segment liabilities</b>	<u>23,522</u>	<u>41,200</u>	<u>2,906</u>	<u>3,784</u>	<u>7,784</u>	<u>5,213</u>	<u>34,212</u>	<u>50,197</u>

<sup>a</sup> Refer to Note 20 for further information.

## 3C. Geographical information

	<b>Group</b>			
	<b><u>2H2025</u></b> RMB'000	<b><u>2H2024</u></b> RMB'000 <i>Restated</i>	<b><u>FY2025</u></b> RMB'000	<b><u>FY2024</u></b> RMB'000 <i>Restated</i>
<b>Revenue</b>				
People's Republic of China	81,885	93,006	167,109	174,897
Singapore	2,344	1,460	3,939	2,588
<b>Total</b>	<b>84,229</b>	<b>94,466</b>	<b>171,048</b>	<b>177,485</b>

	<b>Group</b>	
	<b><u>FY2025</u></b> RMB'000	<b><u>FY2024</u></b> RMB'000
<b>Non-current assets</b>		
People's Republic of China	166,015	179,600
Singapore	8,072	7,325
<b>Total</b>	<b>174,087</b>	<b>186,925</b>

## 4. Revenue

	<b>Group</b>			
	<b><u>2H2025</u></b> RMB'000	<b><u>2H2024</u></b> RMB'000 <i>Restated</i>	<b><u>FY2025</u></b> RMB'000	<b><u>FY2024</u></b> RMB'000 <i>Restated</i>
<u>Revenue classified by nature type</u>				
Rendering of services	44,818	53,951	97,682	104,327
Sale of goods	24,241	23,971	44,140	41,639
Laboratory services	11,880	12,034	23,890	22,829
Management fee income	3,232	4,431	5,221	8,381
Leasing income	58	58	115	274
Other income	–	21	–	35
<b>Total revenue</b>	<b>84,229</b>	<b>94,466</b>	<b>171,048</b>	<b>177,485</b>

<u>Revenue classified by timing of revenue recognition</u>				
Point in time	80,939	89,977	165,712	168,830
Over time	3,290	4,489	5,336	8,655
	<b>84,229</b>	<b>94,466</b>	<b>171,048</b>	<b>177,485</b>

## 5. Other income and gains and (other losses)

	<b>Group</b>			
	<b><u>2H2025</u></b> <b>RMB'000</b>	<b><u>2H2024</u></b> <b>RMB'000</b>	<b><u>FY2025</u></b> <b>RMB'000</b>	<b><u>FY2024</u></b> <b>RMB'000</b>
Bad debts reversal/ (written-off)	264	(56)	(522)	(56)
Foreign exchange adjustment gains/(losses), net	1,176	35	(415)	38
Government grant income	3,028	1,296	4,721	2,053
Rental discount /waiver	381	516	753	740
Gain on remeasurement/de-recognition of right-of-use assets	403	347	226	465
Non-trade payables written-off	19	2	40	155
Inventories written back/(written-down)	80	(69)	107	(70)
Other losses	(2)	(9)	(8)	(34)
Penalty	(77)	(18)	(84)	(18)
Compensation to staff	(241)	–	(241)	–
Compensation of legal case	(280)	–	(280)	–
Compensation on early termination of lease	(178)	(58)	(278)	(58)
Compensation received from insurance	–	41	–	41
Other gains	3	4	10	20
Net reversal/(allowance) for impairment on trade receivables	42	39	(8)	13
Impairment allowance on non-trade receivables	–	–	(500)	–
Loss on disposal of property, plant and equipment	(98)	–	(96)	–
Plant and equipment written-off	(204)	(575)	(278)	(576)
<b>Net</b>	<b><u>4,316</u></b>	<b><u>1,495</u></b>	<b><u>3,147</u></b>	<b><u>2,713</u></b>
Presented in profit or loss as:				
Other income and gains	5,396	2,280	5,857	3,525
Other losses	(1,080)	(785)	(2,710)	(812)
	<b><u>4,316</u></b>	<b><u>1,495</u></b>	<b><u>3,147</u></b>	<b><u>2,713</u></b>

## 6. Finance costs

	<b>Group</b>			
	<b><u>2H2025</u></b> <b>RMB'000</b>	<b><u>2H2024</u></b> <b>RMB'000</b>	<b><u>FY2025</u></b> <b>RMB'000</b>	<b><u>FY2024</u></b> <b>RMB'000</b>
Interest on borrowings	–	6	2	16
Interest on lease liabilities	454	721	965	1,473
	<b><u>454</u></b>	<b><u>727</u></b>	<b><u>967</u></b>	<b><u>1,489</u></b>

## 7. Income tax

	<b>Group</b>			
	<b>2H2025</b> RMB'000	<b>2H2024</b> RMB'000	<b>FY2025</b> RMB'000	<b>FY2024</b> RMB'000
<u>Current tax expense</u>				
Current tax expense	245	296	520	498
Under provision in respect of prior years	973	–	1,054	55
Subtotal	<u>1,218</u>	<u>296</u>	<u>1,574</u>	<u>553</u>
<u>Deferred tax (income)/ expense</u>				
Deferred tax (income)/ expense	<u>(71)</u>	<u>1,056</u>	<u>(142)</u>	<u>955</u>
<u>Withholding tax expense</u>				
Current withholding tax expense	14	16	30	29
Over provision in respect of prior years	–	–	–	(111)
Subtotal	<u>14</u>	<u>16</u>	<u>30</u>	<u>(82)</u>
Total income tax expense	<u>1,161</u>	<u>1,368</u>	<u>1,462</u>	<u>1,426</u>

There are no income tax consequences of dividends to owners of the Company.

Subject to the agreement by the tax authorities, the Group has unutilised tax losses of approximately RMB34.1 million (2024: RMB31.2 million) respectively at the reporting date available for offset against future profits.

As at 31 December 2025, no deferred tax liability has been recognised for withholding tax that would be payable on the undistributed profits of the PRC subsidiaries as management has decided these PRC subsidiaries will not distribute these profits in the foreseeable future.

## 8. Earnings / (Loss) per share

	<b>Group</b>			
	<b>2H2025</b> RMB cents	<b>2H2024</b> RMB cents <i>Restated</i>	<b>FY2025</b> RMB cents	<b>FY2024</b> RMB cents <i>Restated</i>
Basic earnings/ (loss) per share	0.79	(2.52)	1.30	(1.56)
Diluted earnings/ (loss) per share <sup>(a)</sup>	0.79	(2.52)	1.30	(1.56)
Weighted average number of share:-				
Basic and diluted	<u>535,346,363</u>	<u>511,291,824</u>	<u>535,346,363</u>	<u>511,291,824</u>

The earnings/ loss per share is computed by dividing the profit/ loss net of tax attributable to owners of the Company against the weighted average number of shares for the respective reporting periods.

<sup>(a)</sup> The basic and diluted earnings/ loss per share are the same as there were no other outstanding convertibles or other dilutive equity instruments.

9. During the year, the Group acquired property, plant and equipment amounting to RMB2,206,000 (FY2024: RMB2,093,000) and wrote off property, plant and equipment with carrying value of RMB278,000 (FY2024: RMB576,000). There was disposal of property, plant and equipment with carrying value of RMB354,000 (FY2024: nil) during the year for proceeds of RMB257,000, resulting in a loss of RMB96,000. There was no impairment and disposal of property, plant and equipment during the year (FY2024: nil).

**10. Goodwill**

There was no movement in the carrying amount of goodwill during the reporting period.

The cash flow forecasts have been used to perform impairment assessment of goodwill, property, plant and equipment, right-of-use assets and investments in subsidiaries. Since the beginning of the reporting period, there were no significant changes in the circumstances and key assumptions used in the cash flow forecasts. No impairment loss was recognised as the recoverable amounts were higher than the carrying values of these assets at the end of the reporting year.

**11. Investment in an associate**

	<u>Group</u>		<u>Company</u>	
	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000
Unquoted equity shares	6,794	6,716	6,794	6,716
Balance at beginning of the year	6,716	20,897	6,716	20,897
Foreign exchange adjustments	107	56	107	56
Share of results for the year	(29)	(14,237)	–	–
Impairment loss	–	–	(29)	(14,237)
Balance at end of the year	<u>6,794</u>	<u>6,716</u>	<u>6,794</u>	<u>6,716</u>

The carrying value of the investment of an associate was tested for impairment as at 31 December 2025. No further impairment is required in FY2025 as the net asset value of the associate is approximately the carrying amount of the cost of investment in the associate.

**12. Share capital**

	<b>Group and Company</b>	
	<u>Number</u> <u>of shares</u> '000	<u>Share</u> <u>Capital</u> RMB'000
<u>Ordinary shares</u>		
Balance as at 1 January 2024 and 30 June 2024	511,289	445,473
Issuance of new shares <sup>(a)</sup>	233	250
Balance as at 31 December 2024 and 30 June 2025	511,522	445,723
Issuance of new shares <sup>(b)</sup>	511,522	82,801
Balance as at 31 December 2025	<u>1,023,044</u>	<u>528,524</u>

(a) On 24 December 2024, pursuant to the performance shares granted under the Aoxin Q & M Performance Share Plan, the Company issued 233,413 new ordinary shares amounting to RMB250,000 to Dr Yang Li. These shares are held in trust by Honour Pte. Ltd. as Dr Yang Li is a PRC national.

(b) As announced on 11 December 2025, the Company completed the rights issue of 511,522,048 shares on the basis of one (1) Rights Share for every one (1) existing ordinary share in the issued share capital of the Company at an issue price of S\$0.03 per share and had raised gross proceeds of S\$15,346,000, which were translated to RMB83,861,000 at the exchange rate on the date of receipt. After deducting share issue expenses of RMB1,060,000, the net proceeds amounted to RMB82,801,000. Please refer to Note 13 below for further details.

**12. Share capital (cont'd)**

Share options

As at 31 December 2025, there were no outstanding share options (2024: Nil).

Share awards

On 30 December 2025, the Company granted 20 million ordinary shares at S\$0.148 each share pursuant to the Performance Share Plan to a group of high-performing employees, including doctors, nurses and HQ team members. As at 31 December 2025, the total number of share awards outstanding under Aoxin Q & M Performance Share Plan was 20 million shares (2024: nil).

As at 31 December 2025, the issued and paid-up share capital excluding treasury shares of the Company comprised 1,023,044,096 (2024: 511,522,048) ordinary shares.

Save as disclosed above, there were no subsidiary holdings, treasury shares or outstanding convertibles as at 31 December 2025 and 31 December 2024.

**13. Use of proceeds from rights issue**

During the reporting year, the Company undertook a rights issue which raised gross proceeds of S\$15,346,000, which were translated to RMB83,861,000 at the exchange rate on the date of receipt.

	<b>RMB'000</b>
Gross proceeds from rights issue	83,861
Less: share issue expenses	(1,060)
<b>Net proceeds</b>	<u>82,801</u>
Utilised during the financial year	–
<b>Unutilised balance as at year end</b>	<u><u>82,801</u></u>

Intended use of Rights Issue proceeds

<b>Intended use of Rights Issue proceeds</b>	<b>RMB'000</b>	<b>Utilised RMB'000</b>	<b>Balance RMB'000</b>
Investment in property, plant and equipment	27,325	–	27,325
Expansion of business through organic growth, mergers and acquisitions, joint ventures and partnership	43,720	–	43,720
General working capital requirements	11,756	–	11,756
<b>Total</b>	<u>82,801</u>	–	<u>82,801</u>

**14. Other financial liabilities – borrowings and debt securities**

	<b>Unsecured</b>	
	<b>FY2025 RMB'000</b>	<b>FY2024 RMB'000</b>
<u>Group and Company</u>		
Repayable in one year or less, or on demand:		
Bank loan	–	339

The unsecured bank loan relating to a 5-year temporary bridging loan (“TBL”) extended by a bank in Singapore was fully repaid in FY2025. The TBL was repaid over 60 monthly instalments with fixed interest rate of 2.25% per annum.

15. Net assets value

	<u>Group</u>		<u>Company</u>	
	<u>FY2025</u> RMB cents	<u>FY2024</u> RMB cents <i>Restated</i>	<u>FY2025</u> RMB cents	<u>FY2024</u> RMB cents
Net assets value per ordinary share	34.1	50.6	43.9	70.7

The net asset value per ordinary share of the Group and of the Company have been calculated based on the total issued number of ordinary shares of 1,023,044,096 as at 31 December 2025 (31 December 2024: 511,522,048).

16. Related party transactions

There are transactions and arrangements between the Group and its related parties and the effects of these on the basis determined between the parties are reflected in these consolidated financial statements. The related party balances and any financial guarantees are unsecured, without fixed repayment terms and interest or charge unless stated otherwise.

Intragroup transactions and balances that have been eliminated in these consolidated financial statements are not disclosed as related party transactions and balances below.

During the reporting year, certain subsidiaries in the Group leased clinics, hospitals and offices from their directors, and the Company leased software from a related party. The total carrying values of right-of-use assets related to these leases as at the end of the reporting year are as follows:

	<u>Group</u>		<u>Company</u>	
	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000
Carrying values of right-of-use assets	1,692	3,175	291	489

Other than above, the Group also carried out transactions with related parties during the reporting year as follows:

	<u>Group</u>	
	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000
Revenue from laboratory services	3,939	2,588
Management fee	(660)	(467)
Rental expenses	(197)	(201)

17. Categories of financial assets and liabilities

The following table categorises the carrying amounts of financial assets and financial liabilities recorded at the end of the reporting year:

	<u>Group</u>		<u>Company</u>	
	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000 <i>Restated</i>	<u>FY2025</u> RMB'000	<u>FY2024</u> RMB'000
Financial assets at amortised cost	197,375	109,845	128,059	46,995
Financial liabilities at amortised cost	32,241	46,242	2,287	3,996

### 18. Contingent liabilities and contingent assets

There are no material contingent liabilities and contingent assets as at date of this set of financial statements.

### 19. Capital commitments

As at 31 December 2025, there was no committed future capital expenditure not recognised in the financial statements (31 December 2024: nil).

### 20. Restatement of prior period financial statements

During the reporting year, upon the request of the National Healthcare Security Administration 国家医疗保障局 (“NHSA”), a Chinese government agency that oversees, *inter alia*, the nation’s health insurance plan and centralised purchasing of drugs and medical supplies, the Group conducted a self-review exercise on two of our hospitals, namely Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. and Shenyang City Shenhe District No. 6 Hospital (Shenyang Aoxin Q & M Stomatology Hospital Co., Ltd. – Branch Hospital) (the “Hospitals”). Further to the self-review, NHSA and the Hospitals concluded that there was an excess claim of cost of material from NHSA amounting to approximately RMB6.2 million for FY2024, of which RMB3.7million had been refunded to NHSA in June 2025. Please refer to the Company’s announcement dated 22 June 2025. The remaining balance overclaimed amount of RMB2.5 million had been refunded to NHSA in 3Q2025.

This overclaim resulted in an overstatement of revenue and understatement of liabilities in the twelve-month period ended 31 December 2024. As a result, the overstatement of revenue and understatement of liabilities have been adjusted retrospectively. The consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes of equity, consolidated statement of cash flows and earnings per share of the Group for 1H2024, 2H2024 and FY2024 had since been restated.

The following table summarises the impact of the restatement on the affected line items of 2H2024 and FY2024 financial statements:

<u>Group</u>	<u>Previously reported</u> RMB’000	<u>Adjustment</u> RMB’000	<u>Restated</u> RMB’000
<u>Consolidated Statement of Profit or Loss and Other Comprehensive Income for 2H2024</u>			
Revenue	98,278	(3,812)	94,466
 <u>Consolidated Statement of Changes in Equity as at 31 December 2024</u>			
Accumulated losses	(143,083)	(6,237)	(149,320)
Attributable to owners of the Company	264,896	(6,237)	258,659
Total equity	264,897	(6,237)	258,660
 <u>Consolidated Statement of Changes in Cash Flows for 2H2024</u>			
Loss before tax	(7,726)	(3,812)	(11,538)
Operating cash flows before changes in working capital	17,054	(3,812)	13,242
Trade and other payables	6,234	3,812	10,046

## 20. Restatement of prior period financial statements (cont'd)

	<u>Previously reported</u> RMB'000	<u>Adjustment</u> RMB'000	<u>Restated</u> RMB'000
Consolidated Statement of Profit or Loss and Other Comprehensive Income for the year <u>ended 31 December 2024</u>			
Revenue	183,722	(6,237)	177,485
Consolidated Statements of Financial Position <u>as at 31 December 2024</u>			
Accumulated losses	(143,083)	(6,237)	(149,320)
Trade and other payables	25,214	6,237	31,451
	RMB cents	RMB cents	RMB cents
<u>Earnings /(loss) per share for 2H2024</u>			
Basic	(1.78)	(0.74)	(2.52)
Diluted	(1.78)	(0.74)	(2.52)
<u>Earnings /(loss) per share for the year ended 31 December 2024</u>			
Basic	(0.34)	(1.22)	(1.56)
Diluted	(0.34)	(1.22)	(1.56)
Net assets value per ordinary share <u>as at 31 December 2024</u>	51.8	(1.2)	50.6

## 21. Dividends on equity shares

No dividend has been declared or recommended during the current reporting period and previous corresponding period as the Group is conserving cash for working capital needs.

## 22. Events after the end of the reporting period

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

**OTHER INFORMATION REQUIRED BY CATALIST RULE APPENDIX 7C****1. Review**

The condensed interim consolidated statement of financial position of the Group and of the Company as at 31 December 2025 and the related condensed interim consolidated statement profit or loss and other comprehensive income, condensed interim consolidated statement of changes in equity and condensed interim consolidated statement of cash flows of the Group, and statement of changes in equity of the Company for the reporting year ended and certain explanatory notes have not been audited or reviewed by the Company's auditors.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business****FY2025 vs FY2024****Statement of Profit or Loss and Other Comprehensive Income****Revenue**

The Group's revenue decreased by RMB6.4 million or 3.6% from RMB177.5 million for the financial year ended 31 December 2024 ("FY2024") to approximately RMB171.0 million for the financial year ended 31 December 2025 ("FY2025").

Revenue from primary healthcare segment decreased by 8.8% from RMB113.0 million in FY2024 to RMB103.0 million in FY2025. The decline in primary healthcare revenue was primarily attributable to softer consumer sentiment in China amid a slower macroeconomic environment. Patients were more cautious in their spending behaviour, which resulted in lower average revenue per patient.

Revenue from distribution of dental equipment and supplies segment increased by 6.0% from RMB41.6 million in FY2024 to RMB44.1 million in FY2025. This was mainly due to higher sales for dental equipment from government hospitals.

Revenue from laboratory services segment increased by 4.6% from RMB22.8 million in FY2024 to RMB23.9 million in FY2025. The increase was largely due to higher sales for laboratory business in Singapore.

**Other Income and Gains**

Other income and gains increased by 66.2% or RMB2.3 million from RMB3.5 million in FY2024 to approximately RMB5.9 million in FY2025 mainly due to higher government grant/incentive.

**Expenses****Cost of consumables and dental supplies**

Consumables and dental supplies used decreased by 13.4% from RMB17.3 million in FY2024 to RMB15.0 million in FY2025, which was in line with the decrease in revenue from the primary healthcare segment.

As a percentage of revenue from the primary healthcare segment, cost of consumables and dental supplies used in FY2025 was 14.6% as compared to 15.3% in FY2024.

**Cost of sales in dental equipment and supplies**

Cost of sales in dental equipment and supplies increased by 7.3% from RMB35.7 million in FY2024 to RMB38.3 million in FY2025, which was due to increase in revenue from the distribution of dental equipment and supplies segment.

As a percentage of revenue from the distribution of dental equipment and supplies segment, cost of sales in dental equipment and supplies in FY2025 was 86.7% as compared to 85.7% in FY2024.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business (cont'd)**Cost of laboratory services

Cost of laboratory services decreased by RMB0.6 million or 11.1% to RMB4.6 million in FY2025. The decrease was mainly due to lesser material used and lesser wastage.

As a percentage of revenue from the laboratory services segment, cost of laboratory services was 19.4% in FY2025 as compared to 22.9% in FY2024. The higher gross profit margin of the laboratory segment for FY2025 was mainly due to lower material cost as a result of bulk purchasing and effective inventory control.

Employee benefits expenses

Employee benefits expense decreased by 5.9% from RMB79.4 million in FY2024 to RMB74.7 million in FY2025, due to lower staff commissions in line with the reduction in primary healthcare's revenue.

As a percentage of total revenue, employee benefits expense was 43.7% in FY2025 as compared to 44.7% in FY2024.

Other expenses

Other expenses decreased by 4.9% or RMB0.9 million from RMB18.6 million in FY2024 to RMB17.7 million in FY2025. The decrease was mainly due to decrease in other tax expenses, entertainment expenses, motor vehicles expenses and travelling expenses as a result of better cost control.

As a percentage of total revenue, other expenses in FY2025 slightly decreased to 10.3% from 10.5% in FY2024.

Other losses

Other losses increased RMB1.9 million from RMB0.8 million in FY2024 to RMB2.7 million in FY2025. The increase in other losses was mainly due to the impairment allowance on non-trade receivables due to non-repayment of a loan from the borrower, increase in bad debts written-off after Company's assessment of low likelihood of a successful claim under the medical co-payment scheme from the PRC government, foreign exchange adjustment losses, compensation of legal case and compensation to staff.

Share of results of associate

Share of results of associate reduced to a loss of RMB0.03 million in FY2025 as compared to a loss of RMB14.2 million in FY2024. The loss of RMB0.03 million was mainly for statutory cost as the associate company is currently in a dormant status. Whilst the loss of RMB14.2 million in FY2024 was mainly due to impairment of fixed assets as a result of expiry of laboratory licence and cessation of government contract for Covid-19 vaccination.

Income tax expense

The tax expense was RMB1.5 million in FY2025 as compared to RMB1.4 million in FY2024. The higher tax expense in FY2025 as compared to prior year was largely due to under provision of prior years' income tax expenses.

**Profit/ (loss), net of tax**

For the reasons given above, the Group recorded a net profit of RMB6.9 million in FY2025 as compared to a net loss of RMB8.0 million in FY2024. Profit/(loss) net of tax excluding share of results of associate for FY2025 was profit of RMB7.0 million as compared to a profit of RMB6.2 million in FY2024.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business (cont'd)****2H2025 vs 2H2024****Statement of Profit or Loss and Other Comprehensive Income****Revenue**

The Group's revenue decreased by RMB10.2 million or 10.8%, from RMB94.5 million for the six months ended 31 December 2024 ("2H2024") to approximately RMB84.2 million in 2H2025.

Revenue for primary healthcare segment decreased by 17.7%, from RMB58.5 million in 2H2024 to RMB48.1 million in 2H2025 while laboratory services segment slightly decreased by 1.4%, from RMB12.0 million to RMB11.9 million. The decline in primary healthcare revenue was primarily attributable to softer consumer sentiment in China amid a slower macroeconomic environment. Patients were more cautious in their spending behaviour, which resulted in lower average revenue per patient.

Revenue from distribution of dental equipment and supplies segment slightly increased by 1.1%, from RMB24.0 million in 2H2024 to RMB24.2 million in 2H2025.

**Other Income and Gains**

Other income and gains increased by RMB3.1 million from RMB2.3 million in 2H2024 to RMB5.4 million in 2H2025 mainly due to higher government grant/incentive, foreign exchange adjustment gain, and reversal of bad debts.

**Expenses****Cost of consumables and dental supplies**

Consumables and dental supplies used decreased by 20.6% from RMB8.9 million in 2H2024 to RMB7.1 million in 2H2025, which was in line with the decrease in revenue from the primary healthcare segment.

As a percentage of revenue from the primary healthcare segment, cost of consumables and dental supplies used in 2H2025 was 14.8% as compared to 15.3% in 2H2024.

**Cost of sales in dental equipment and supplies**

Cost of sales in dental equipment and supplies slightly decreased by 0.2% from RMB20.91 million in 2H2024 to RMB20.86 million in 2H2025.

As a percentage of revenue from the distribution of dental equipment and supplies segment, cost of sales in dental equipment and supplies in 2H2025 was 86.0% as compared to 87.2% in 2H2024.

**Cost of laboratory services**

Cost of laboratory services decreased by 10.6% from RMB2.6 million in 2H2024 to RMB2.3 million in 2H2025 due to lesser material used and lesser wastage.

As a percentage of revenue from the laboratory services segment, cost of laboratory services was 19.4% in 2H2025 as compared to 21.4% in 2H2024. Higher gross margin was mainly due to better material cost and effective inventory control.

**Employee benefits expenses**

Employee benefits expense decreased by 8.6% from RMB40.0 million in 2H2024 to RMB36.6 million in 2H2025 due to lower staff commissions in line with the reduction in primary healthcare's revenue.

As a percentage of total revenue, employee benefits expense was 43.5% in 2H2025 as compared to 42.4% in 2H2024.

**Depreciation and amortisation expenses**

Depreciation and amortisation expenses increased by 9.7% from RMB4.0 million in 2H2024 to RMB4.3 million in 2H2025. The increase was mainly due to acquisition of new dental equipment during the year.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business (cont'd)**

Other expenses

Other expenses decreased by 17.9% from RMB10.1 million in 2H2024 to RMB8.3 million in 2H2025. The decrease was mainly due to decrease in other tax expenses, entertainment expenses, motor vehicles expenses and travelling expenses as a result of better cost control.

As a percentage of total revenue, other expenses in 2H2025 decreased to 9.9% from 10.7% in 2H2024.

Other losses

Other losses increased by 37.6% from RMB0.8 million in 2H2024 to RMB1.1 million in 2H2025. The increase was mainly due to the increase in compensation of legal case and compensation to staff.

Share of results of associate

Share of results of associate was a loss of RMB0.3 million in 2H2025 as compared to a loss of RMB16.9 million in 2H2024. The loss of RMB0.3 million was due to the current dormant status of the associate. While the loss of RMB16.9 million was mainly due to impairment of fixed assets in FY2024 as a result of expiry of laboratory licence and cessation of government contract for Covid-19 vaccination.

Income tax expense

The tax expense was RMB1.2 million in 2H2025 as compared to RMB1.4 million in 2H2024. The lower tax expense in 2H2025 as compared to prior year was largely due to deferred tax expenses recognised in 2H2024 and offset by higher tax for 2H2025.

**Profit/ (loss), net of tax**

For the reasons given above, the Group recorded a net profit of RMB4.2 million in 2H2025 as compared to a net loss of RMB12.9 million in 2H2024. Profit, net of tax excluding share of results of associate for 2H2025 was RMB4.5 million as compared to RMB4.0 million in 2H2024.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business (cont'd)****Statement of Financial Position**

The comparative performance for both the assets and liabilities is based on the Group's financial position as at 31 December 2025 and 31 December 2024.

**Non-Current Assets**

Property, plant and equipment decreased by RMB6.2 million, from RMB28.4 million as at 31 December 2024 to RMB22.2 million as 31 December 2025. The decrease was mainly due to depreciation during the year.

Right-of-use (“**ROU**”) assets decreased by RMB5.9 million, from RMB23.4 million as at 31 December 2024 to RMB17.5 million as at 31 December 2025, mainly due to depreciation of ROU assets. The Group's ROU assets are related to premises leased by the Group for its dental centres and business units.

**Current Assets**

Trade and other receivables increased by RMB8.8 million, from RMB39.9 million as at 31 December 2024 to RMB48.7 million as at 31 December 2025. The increase was largely due to an increase in trade receivables as a result of slower receipt of payment from government hospitals and laboratory business in Singapore.

Cash and cash equivalents increased by RMB78.8 million, from RMB69.9 million as at 31 December 2024 to RMB148.7 million as at 31 December 2025. For details on fluctuation of cash and cash equivalents, please refer to the cash flow movements analysis below.

**Non-Current Liabilities**

Lease liabilities decreased by RMB3.7 million, from RMB10.9 million as at 31 December 2024 to RMB7.2 million as at 31 December 2025 mainly due to payment of lease liabilities.

**Current Liabilities**

Trade and other payables decreased by RMB10.2 million, mainly due to excess claim of cost of material of RMB6.2 million from National Healthcare Security Administration (“**NHSA**”) in FY2024 as a result of self-review exercise conducted in 1H2025. The amount of excess claim of RMB6.2 million had been restated to FY2024 and had been fully repaid to NHSA in FY2025. In addition, the decrease was also due to reduction in accrual of employee costs and VAT.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business (cont'd)**

**FY2025 vs FY2024**

**Statement of Cash Flows**

The Group's net cash flows generated from operating activities in FY2025 was RMB4.1 million. This was mainly attributable to operating cash inflows before changes in working capital of RMB25.7 million and partially offset by decrease in trade and other payables of RMB10.2 million and increase in trade and other receivables of RMB9.8 million.

Net cash used in investing activities in FY2025 was RMB1.9 million, which was mainly due to acquisition of plant and equipment for the Group's operations.

Net cash flows generated from financing activities in FY2025 was RMB76.2 million, mainly due to rights issue exercise which raised net proceeds of RMB82.8 million and partially offset by the repayment of lease liabilities and interest as well as repayment of bank loan.

As a result of the above, the Group's cash and cash equivalents stood at RMB148.7 million as at 31 December 2025.

**2H2025 vs 2H2024**

**Statement of Cash Flows**

The Group's net cash flows generated from operating activities in 2H2025 was RMB4.3 million. This was mainly attributable to operating cash inflows before changes in working capital of RMB16.2 million and partially offset by decrease in trade and other payables of RMB5.6 million and increase in trade and other receivables of RMB6.3 million.

Net cash flows used in investing activities in 2H2025 was RMB0.8 million, which was mainly due to acquisition of plant and equipment for the Group's operations.

Net cash flows generated from financing activities in 2H2025 was RMB79.2 million, mainly due to rights issue exercise which raised net proceeds of RMB82.8 million and partially offset by the repayment of lease liabilities and interest.

As a result of the above, the Group's cash and cash equivalents stood at RMB148.7 million as at 31 December 2025.

**3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results**

Not applicable.

#### 4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months

The Board believes that the dental services sector in China will continue to remain challenging over the next 12 months. While overall consumer sentiment remains cautious and price-sensitive, rising oral health awareness, demographic ageing and greater acceptance of preventive and restorative treatments continue to support long-term demand. Competition remains intense, particularly among private dental chains, placing greater emphasis on service quality, brand trust and operational efficiency.

As a licensed medical institution, the Group is subject to strict regulatory requirements which are constantly evolving, including the national basic medical insurance (医保统筹) framework. Regulatory oversight and compliance inspections by local authorities in the dental sector have increased, particularly in relation to medical insurance fund utilisation and treatment documentation. The Group will continue to strengthen its compliance management systems to maximise the benefits of being an approved dental hospital under the medical insurance scheme.

National centralised volume-based procurement (集采) policies for dental implants and related consumables remain in force and are expected to continue exerting margin pressure on implantology services. The Group will focus on strengthening cost controls and enhancing clinical efficiency, particularly through digital dentistry and adoption of AI, to mitigate margin impact.

Our Group is also expanding our lab services businesses into Singapore and other regional countries, to tap into the strong demand for dental lab services in Southeast Asia.

In the fourth quarter of 2025, the Group successfully completed a Rights Issue, raising net proceeds of approximately S\$15.0 million. The capital raise has significantly strengthened the Group's balance sheet and liquidity position, providing financial flexibility to pursue strategic growth initiatives. As disclosed, approximately S\$8.0 million of the net proceeds have been earmarked for business expansion through organic growth, mergers and acquisitions, joint ventures and strategic partnerships, while S\$5.0 million will be allocated towards investment in property, plant and equipment, with the balance for general working capital requirements. The strengthened capital base positions the Group to capitalise on consolidation opportunities within the dental services sector.

The dental services industry in China is undergoing a period of consolidation, driven by intensified competition, pricing pressures from centralised procurement policies, rising operating costs and stricter regulatory oversight. These factors have placed financial strain on certain smaller dental operators, creating selective acquisition opportunities for the Group. The Group intends to deploy the RMB43.7 million (or S\$8.0 million) expansion allocation to pursue acquisition opportunities, particularly targeting established dental clinic chains outside North-Eastern China, where the Group currently operates. Depending on the size of the potential targets, acquisitions are expected to be funded through a combination of cash and, where appropriate, the issuance of new shares of the Company, thereby preserving liquidity while aligning the interests of incoming partners with the long-term growth of the Group. Such geographic diversification is expected to broaden the Group's market footprint, reduce regional concentration risk and generate operational synergies through standardised clinical protocols, procurement leverage and shared management expertise.

Overall, notwithstanding regulatory and pricing headwinds, the Board is optimistic that the Group is well positioned to navigate industry changes and capture sustainable growth opportunities through disciplined management, clinical excellence and operational scale.

Barring any unforeseen circumstances, there are no known significant changes in the trends and competitive conditions in which the Group operates and no other known factors or events that may adversely affect the Group in the next twelve (12) months.

**5. Dividend**

**(a) Current financial period reported on**

**Any dividend declared for the current financial period reported on?**

None.

**(b) Corresponding period of the immediately preceding financial year**

**Any dividend declared for the corresponding period of the immediately preceding financial year?**

None.

**(c) The date the dividend is payable.**

Not applicable.

**(d) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined**

Not applicable.

**6. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.**

No dividend has been declared or recommended for FY2025 as the Group is conserving cash for its working capital needs.

**7. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year.**

Please refer to Note 3B to the condensed interim consolidated financial statements.

**8. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business segments.**

**Performance by business segment**

Please refer to explanation in Paragraph 2 of Other Information Required By Appendix 7C of the Catalist Rules in this announcement.

9. A breakdown of sales

In RMB'000	Group		Change %
	FY2025	FY2024 Restated <sup>a</sup>	
Revenue reported for first half year	86,819	83,019	4.6
Profit/(Loss) after tax reported for first half year	2,736	4,909	(44.3)
Revenue reported for second half year	84,229	94,466	(10.8)
Profit/(Loss) after tax reported for second half year	4,198	(12,906)	NM

NM: Not meaningful.

<sup>a</sup> Refer to Note 20 for further information.

10. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

Not applicable. No dividend has been declared or recommended for FY2025 and FY2024.

11. Interested person transactions

The Group has not obtained a general mandate from shareholders for interested person transactions pursuant to Rule 920 of the Catalist Rules. Particulars of the interested person transactions for FY2025, disclosed in accordance with Rule 907 of the Catalist Rules, are set out below:

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920 of the Catalist Rules)	Aggregate value of all interested person transactions conducted under the shareholders' mandate pursuant to Rule 920 of the Catalist Rules (excluding transactions less than S\$100,000)
Singapore Dental Cadcam Laboratory Pte Ltd	Subsidiary of Q & M Dental Group (Singapore) Limited, a controlling shareholder of the Company	S\$716,000*	None
		Revenue from laboratory services segment	
		S\$156,000*	
		Other expenses	

\* RMB5.50 to SGD1

12. Confirmation pursuant to Rule 720(1) of the Catalist Rules

The Company hereby confirms that it has procured undertakings from all its directors and executive officers under Rule 720(1) of the Catalist Rules.

13. **Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) of the Catalist Rules in the format below. If there are no such persons, the issuer must make an appropriate negative statement.**

No person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) of the Catalist Rules.

14. **Disclosure on incorporation, acquisition and realization of shares pursuant to Catalist Rule 706A**

The Company struck off three wholly-owned subsidiaries, namely Shenyang Aoxin Jinfeng Dental Clinic Co., Ltd. (which was dormant), Anshan Lishan District Aoxin Q & M Stomatology Polyclinic Co., Ltd. and Shenyang Huanggu Aoxin Dental Clinic Co., Ltd. on 14 July 2025, 25 June 2025 and 2 September 2025 respectively. The latter two subsidiaries were struck off as part of the Group's organisation rationalisation and process streamlining.

Separately, the Group incorporated a 49%/51% joint venture company with Q & M Dental Group (Singapore) Limited's wholly owned subsidiary, to carry out the provision of laboratory services including processing of porcelain crown, bridges and dentures, and development of dental inlay technology. Please refer to further details as announced on 12 September 2025.

**On behalf of the board of directors**

**Mr. Chua Ser Miang**  
**Non-Executive Chairman and**  
**Independent Director**

28 February 2026

**Ms. Ng Sook Hwa**  
**Non-Independent Non-Executive**  
**Director**

28 February 2026